AOD-9604vsHGH Fragment 176-191

AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance.

The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes.

Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.

HGH Fragment 176-191 is the unmodified C-terminal segment of human growth hormone, representing exactly the last 16 amino acids of the 191-amino-acid GH molecule. Research identified this region as containing the molecular determinants responsible for GH's lipolytic activity, independent of the N-terminal domain that binds the growth hormone receptor and drives IGF-1 production and tissue growth.

The fragment activates lipolysis in white adipose tissue through interaction with beta-adrenergic signaling pathways. This triggers the cAMP/protein kinase A cascade that phosphorylates and activates hormone-sensitive lipase and perilipin proteins on the surface of lipid droplets within fat cells. The result is the breakdown of stored triglycerides into free fatty acids and glycerol, which are released into circulation for oxidation by energy-demanding tissues such as skeletal muscle and the liver.

Because the fragment lacks the binding regions for the GH receptor (located in amino acids 1-175), it does not activate the JAK2-STAT5 signaling pathway responsible for hepatic IGF-1 synthesis, somatic growth, or the insulin-antagonistic effects of full-length growth hormone. However, the shorter half-life compared to AOD-9604 (which has an additional stabilizing tyrosine residue) means more frequent dosing is required, and clinical evidence supporting its efficacy in humans remains very limited.